Status:
TERMINATED
Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection
Lead Sponsor:
West China Hospital
Conditions:
Carcinoma, Non-Small-Cell Lung
Chemotherapy, Adjuvant
Eligibility:
All Genders
18+ years
Brief Summary
This study will establish a multi-center, prospective registration database. The included population are stage II and IIIA NSCLC patients undergoing R0 resection and will be scheduled for adjuvant che...
Eligibility Criteria
Inclusion
- Age 18 or older;
- Pathological diagnosis of patients with stage II, III A primary NSCLC;
- R0 resection has been accepted;
- Received adjuvant chemotherapy or adjuvant chemotherapy for the first time after surgery;
- Informed consent has been signed.
Exclusion
- Incorporation of other malignant tumors (such as leukemia, liver cancer, etc.)；
- Patients with unclear pathological types；
- Patients with unclear pathological staging；
- Preserved Shenlingcao Oral Liquid before R0 resection surgery；
- Received immunotherapy or targeted therapy before R0 resection surgery；
- Radiotherapy and chemotherapy before R0 resection surgery.
Key Trial Info
Start Date :
March 28 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 10 2018
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT03479294
Start Date
March 28 2018
End Date
September 10 2018
Last Update
August 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, China, 300051